Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a multicentre, open-label, first in man, study of a novel NanoZolid®-docetaxel depot
formulation (NZ-DTX Depot) given as an intra-tumoural injection in patients with advanced
solid tumours. The study includes a dose escalation part and a dose expansion part.